Trial Profile
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Ezetimibe; Fenofibrate; HMG-CoA reductase inhibitors; Nicotinic acids; Omega 3 fatty acids
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Acronyms ODYSSEY DM-Dyslipidemia
- Sponsors Sanofi
- 11 Jun 2019 Results of post hoc subgroup analysis of ODYSSEY DM-DYSLIPIDEMIA trial investigating effect of Alirocumab in individuals with type 2 diabetes and high triglycerides and low high-density lipoprotein cholesterol presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 21 Jun 2017 Status changed from active, no longer recruiting to completed.
- 11 Jun 2017 Primary endpoint has been met (Percent change in non-HDL-C in the intent-to-treat (ITT) population), according to a Regeneron Pharmaceuticals media release.